These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12201955)

  • 1. Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.
    Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
    J Hematother Stem Cell Res; 2002 Aug; 11(4):669-74. PubMed ID: 12201955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
    Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
    J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo generation of cytokine-induced killer cells (CD3+ CD56+) from post-stem cell transplant pediatric patients against autologous-Epstein-Barr virus-transformed lymphoblastoid cell lines.
    Petvises S; Pakakasama S; Wongkajornsilp A; Sirireung S; Panthangkool W; Hongeng S
    Pediatr Transplant; 2007 Aug; 11(5):511-7. PubMed ID: 17631019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
    He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
    Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ex vivo inducing cultured Epstein-Barr virus specific cytotoxic T lymphocytes and evaluation of their killing effect].
    Chen GH; Gu B; Chen F; Wang Y; Qiao M; Liu HW; Feng YF; Dai LJ; Zhu ZL; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1597-601. PubMed ID: 24370055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
    Sun Q; Burton RL; Pollok KE; Emanuel DJ; Lucas KG
    Cell Immunol; 1999 Aug; 195(2):81-8. PubMed ID: 10448007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms.
    Sauce D; Bodinier M; Garin M; Petracca B; Tonnelier N; Duperrier A; Melo JV; Apperley JF; Ferrand C; Hervé P; Lang F; Tiberghien P; Robinet E
    Blood; 2002 Feb; 99(4):1165-73. PubMed ID: 11830462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
    Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro.
    Kabelitz D; Herzog WR; Heeg K; Wagner H; Reimann J
    J Mol Cell Immunol; 1987; 3(1):49-60. PubMed ID: 2855406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
    J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.